Valsartan

"Valsartan" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION.

Descriptor ID	D000068756
MeSH Number(s)	D03.383.129.617.850 D12.125.070.950.550 D12.125.142.930.500
Concept/Terms	Valsartan Valsartan N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine Diovan Diovan Kalpress Kalpress Tareg Tareg Nisis Nisis Provas Provas Vals Vals CGP 48933 CGP 48933 48933, CGP Miten Miten

Below are MeSH descriptors whose meaning is more general than "Valsartan".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Azoles [D03.383.129]
Tetrazoles [D03.383.129.617]
Valsartan [D03.383.129.617.850]
Amino Acids, Peptides, and Proteins [D12]
Amino Acids [D12.125]
Amino Acids, Branched-Chain [D12.125.070]
Valine [D12.125.070.950]
Valsartan [D12.125.070.950.550]
Amino Acids, Essential [D12.125.142]
Valine [D12.125.142.930]
Valsartan [D12.125.142.930.500]

Below are MeSH descriptors whose meaning is related to "Valsartan".

Below are MeSH descriptors whose meaning is more specific than "Valsartan".

Valsartan
Amlodipine, Valsartan Drug Combination

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Valsartan" by people in this website by year, and whether "Valsartan" was a major or minor topic of these publications.

Bar chart showing 9 publications over 8 distinct years, with a maximum of 2 publications in 2022

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2003	0	1	1
2006	0	1	1
2007	0	1	1
2018	1	0	1
2019	1	0	1
2020	0	1	1
2021	0	1	1
2022	1	1	2

Below are the most recent publications written about "Valsartan" by people in Profiles.

Gabot A, Lavitas P, Bacon R, Pomfret TC, Taylor M, Coelho A, Greenwood BC, Alper CJ, Clements KM, Lenz K. Cost-benefit analysis of sacubitril/valsartan in a Medicaid population. Am J Manag Care. 2022 07; 28(7):349-352.

View in: PubMed
Mann DL, Givertz MM, Vader JM, Starling RC, Shah P, McNulty SE, Anstrom KJ, Margulies KB, Kiernan MS, Mahr C, Gupta D, Redfield MM, Lala A, Lewis GD, DeVore AD, Desvigne-Nickens P, Hernandez AF, Braunwald E. Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA Cardiol. 2022 01 01; 7(1):17-25.

View in: PubMed
Kim YS, Brar S, D'Albo N, Dey A, Shah S, Ganatra S, Dani SS. Five Years of Sacubitril/Valsartan-a Safety Analysis of Randomized Clinical Trials and Real-World Pharmacovigilance. Cardiovasc Drugs Ther. 2022 10; 36(5):915-924.

View in: PubMed
Dani SS, Ganatra S, Vaduganathan M. Angioedema with sacubitril/valsartan: Trial-level meta-analysis of over 14,000 patients and real-world evidence to date. Int J Cardiol. 2021 01 15; 323:188-191.

View in: PubMed
Maslov MY, Foianini S, Mayer D, Orlov MV, Lovich MA. Interaction Between Sacubitril and Valsartan in Preventing Heart Failure Induced by Aortic Valve Insufficiency in Rats. J Card Fail. 2019 Nov; 25(11):921-931.

View in: PubMed
Maslov MY, Foianini S, Mayer D, Orlov MV, Lovich MA. Synergy between sacubitril and valsartan leads to hemodynamic, antifibrotic, and exercise tolerance benefits in rats with preexisting heart failure. Am J Physiol Heart Circ Physiol. 2019 02 01; 316(2):H289-H297.

View in: PubMed
Solomon SD, Janardhanan R, Verma A, Bourgoun M, Daley WL, Purkayastha D, Lacourci?re Y, Hippler SE, Fields H, Naqvi TZ, Mulvagh SL, Arnold JM, Thomas JD, Zile MR, Aurigemma GP. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet. 2007 Jun 23; 369(9579):2079-87.

View in: PubMed
Janardhanan R, Daley WL, Naqvi TZ, Mulvagh SL, Aurigemma G, Zile M, Arnold JM, Artis E, Purkayastha D, Thomas JD, Solomon SD. Rationale and design: the VALsartan In Diastolic Dysfunction (VALIDD) Trial: evolving the management of diastolic dysfunction in hypertension. Am Heart J. 2006 Aug; 152(2):246-52.

View in: PubMed
Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, Glazer RD, Tognoni G, Cohn JN. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2003 Mar 11; 107(9):1278-83.

View in: PubMed

People

Explore

Similar Concepts

Top Journals